Replicor 成功確認 NAP 靶向乙型肝炎亞病毒顆粒

StephenW

Replicor 成功確認 NAP 靶向乙型肝炎亞病毒顆粒

蒙特利爾，2022 年 4 月 4 日——Replicor Inc. 宣佈在其 REP 301 和 REP 401 臨床研究中成功確認 NAP 靶向乙型肝炎亞病毒顆粒 (SVP)。

治療期間需要清除 SVP 以實現 HBV 的功能性治愈；循環 HBsAg 由 >99.99% 的非感染性 SVP 組成，這會阻止對感染的免疫控制。臨床上 SVP 的有效清除可以通過 HBsAg 的小異構體 (S-HBsAg) 的選擇性下降來證實，該異構體獨特地富含這些顆粒。

在與 Abbott Diagnostics 合作進行的 Hepatology Communications（此處）上發表的一項新分析中，在基於 NAP 的 HBV 單一感染（REP 401 研究）或 HBV / HDV 共感染（REP 301 研究）治療期間快速清除 HBsAg 伴隨著選擇性S-HBsAg 的清除。這些結果證實了 NAP 在人類感染中有效清除 SVP，這與之前在此處和此處的體外機制研究中觀察到的 NAP 對 SVP 組裝和分泌的選擇性抑制一致。

Replicor 的 CSO Andrew Vaillant 博士評論說：“有效清除亞病毒顆粒是實現 HBV 功能性治癒的關鍵步驟。沒有其他正在開發的抗病毒療法（包括 NUC、CAM 或 RNAi）具有這種效果，這是基於 NAP 療法實現 HBV 高功能治愈率的獨特能力的基礎。”

關於 Replicor

Replicor 是一家私營生物製藥公司，在開發 HBV 和 HDV 治療方法方面擁有最先進的動物和人類臨床數據。公司致力於加速開發針對 HBV 和 HBV/HDV 合併感染患者的有效治療方法。有關 Replicor 的更多信息，請訪問我們的網站 www.replicor.com。

StephenW

Replicor successfully confirms NAPs target Hepatitis B subviral particles

MONTREAL, April 4th, 2022 – Replicor Inc., announced the successful confirmation of the targeting of Hepatitis B subviral particles (SVP) by NAPs in its REP 301 and REP 401 clinical studies.

Clearance of SVP during therapy is required to achieve functional cure of HBV; circulating HBsAg is comprised of >99.99% non-infectious SVP, which prevents immune control of infection.  Efficient clearance of SVP in the clinic can be confirmed by the selective decline of the small isoform of HBsAg (S-HBsAg), which is uniquely enriched in these particles.

In a new analysis published in Hepatology Communications (here), performed in collaboration with Abbott Diagnostics, rapid clearance of HBsAg during NAP-based therapy of HBV monoinfection (REP 401 study) or HBV / HDV coinfection (REP 301 study) was accompanied by selective clearance of S-HBsAg.  These results confirm the efficient clearance of SVP by NAPs in human infection, consistent with the selective inhibition of the assembly and secretion of SVP by NAPs observed in previous in vitro mechanistic studies here and here.

Dr. Andrew Vaillant, CSO, Replicor commented, “Efficient clearance of subviral particles is a critical step in achieving functional cure of HBV.  No other antiviral therapy in development (including NUCs, CAMs or RNAi) has this effect, which underlies the unique ability of NAP-based therapy to achieve high rates of functional cure of HBV.”

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.

乙肝人1949

我同意